Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Cutaneous Melanoma Detection and Management, and Immunotherapy and Immune Responses.
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
An analysis of degradation in low-cost particulate matter sensors
Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions
Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma
High-Dimensional and Spatial Analysis Reveals Immune Landscape–Dependent Progression in Cutaneous Squamous Cell Carcinoma
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Antibody Production with Synthetic Peptides
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
HPLC–MTT assay: Anticancer activity of aqueous garlic extract is from allicin
Gold Ion–Angiotensin Peptide Interaction by Mass Spectrometry